Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid switch from pamidronate in breast cancer
NCT00372710Phase 3Terminated
- Sponsor
- Novartis
- Start
- Aug 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronic acid in breast cancer and bone metastasis (2 arms), sponsored by Novartis. Primary endpoint: Efficacy of a switch over from pamidronate therapy to zoledronic acid at 44 weeks. Started Aug 2002; status: terminated.
02
Drugs
zoledronic acid
03
Conditions
breast cancerbone metastasis
Beyond the preview
Go deeper on NCT00372710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00372710.